Our leadership team has a demonstrated track record of taking cell therapies from product inception to the clinic
Our Leadership
Nuno Madeira do Ó
Chief Executive Officer & Co-Founder
Nuno possesses a diverse professional background encompassing both scientific expertise as well as extensive experience in business development and operations within the life sciences sector.
Prior to joining Bastion Therapeutics, Nuno was the Chief Operating Officer at Quest Meat, a start-up dedicated to developing solutions for cultivated meat production.
Before then, Nuno served as the Head of International Business Development at the Cell and Gene Therapy Catapult. During his tenure, he led a highly successful team responsible for overseeing all commercial and collaborative transactions.
Prior to his work at the Cell and Gene Therapy Catapult, Nuno held various positions at renowned companies such as Medimmune/AstraZeneca, Novaliq, and Pion. These roles provided him with invaluable insights into different facets of the life sciences industry, further augmenting his expertise in business development and operations.
Nuno holds a PhD in Advanced Drug Delivery and Tissue Engineering from the University of Nottingham.
Nia Emami
Chief Scientific Officer & Co-Founder
Nia has over 10 years of experience working in the field of cell therapy in both academic and industry settings. He has expertise in developing CAR/TCR therapies and is experienced with both conventional and unconventional T-cells.
Prior to joining Bastion Therapeutics, Nia served as AD - Product Research at Quell Therapeutics developing autologous and allogeneic CAR-Treg therapies for solid organ transplantation, autoimmune and inflammatory diseases. Before that, he served as AD - Preclinical Development at Gadeta focusing on the development of γδ TCR-T therapies for haematological malignancies and solid tumours.
Nia completed his postdoctoral work on CAR T-cell therapies for solid tumours at King’s College London under Dr. Sophie Papa. He holds a PhD in Immunology from the Barts Cancer Institute at Queen Mary University of London.
